Stem Cell Therapy Decreases Covid Deaths
Several clinical studies report increased patient survival following the intravenous infusion of mesenchymal stem cells (MSCs) during the past year. MSCs block the cytokine storm in the lungs and also regenerate cells and tissues damaged by the COVID-19 virus. MSCs are not vaccines and work differently in the treatment of COVID-19.
Also in White Papers
Exosomes Secreted by the Cocultures of Normal and Oxygen–Glucose‐Deprived Stem Cells Improve Post‐stroke Outcome
Emerging stroke literature suggests that treatment of experimentally induced stroke with stem cells offered post-stroke neuroprotection via exosomes produced by these cells. Treatment with exosomes has great potential to overcome the limita- tions associated with cell-based therapies.
Mesenchymal Stem Cell Treatment Prevents Post-Stroke Dysregulation of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
Stem cell treatment is one of the potential treatment options for ischemic stroke. We recently demonstrated a protective effect of human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) in a rat model of ischemic stroke.
Stem Cell Treatment After Cerebral Ischemia Regulates the Gene Expression of Apoptotic Molecules
Evidence suggests that apoptosis contributes significantly to cell death after cerebral ischemia. Our recent studies that utilized human umbilical cord blood- derived mesenchymal stem cells (hUCBSCs) demonstrated the potential of hUCBSCs to inhibit neuronal apoptosis in a rat model of CNS injury.